【大摩:升上海医药(02607.HK)目标价至18港元 评级“增持”】智通财经APP获悉,摩根士丹利发布研报称,对上海医

智通财经
17 Jul
【大摩:升上海医药(02607.HK)目标价至18港元 评级“增持”】智通财经APP获悉,摩根士丹利发布研报称,对上海医药(02607.HK)目标价由17港元升至18港元,相当于预测2026年市盈率9.7倍,评级“增持”。考虑到中期业绩盈喜,该行将上海医药2025至2030年的盈利预测上调1至11%,原因是分销和制造业务的销售额增加。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10